Baird served as co-manager on this offering
AboutAlbireo Pharma, Inc. (“Albireo”) (NASDAQ-CM:ALBO) recently completed an underwritten public offering of 4,000,000 shares of its common stock at a public offering price of $40.00 per share. Albireo’s gross proceeds from this offering are expected to be $160 million. In addition, Albireo has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock at the public offering price, less underwriting discounts and commissions.
Albireo is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo’s lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in progressive familial intrahepatic cholestasis and biliary atresia, with a third Phase 3 trial being planned in Alagille syndrome. Albireo was spun out from AstraZeneca in 2008. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.
CONTACT US TO LEARN MORE
- September 2020
- Albireo Pharma, Inc.
- Target Location
- North America